No Prescription |
 |
 | ||
|
Trivastal (Piribedil) |
|
| ||
No Prescription » Anti Depressants » Trivastal (Piribedil) Trivastal (Piribedil) a reference dopamine agonist effective in two major pathologies Parkinsons disease and cerebral aging. Buy Trivastal (Piribedil) and other Anti Depressants products online at Medstore. Buy Online at Medstore - Click Here!
About Trivastal (Piribedil): Product Type: Anti Depressants Brand name: Trivastal Generic name: Piribedil Indications Treatment of Parkinsons disease either as monotherapy or in combination with L-dopa therapy in the early stages as well as in advanced stages. Treatment of Pathological cognitive deficits in the elderly. Treatment of Dizziness in the elderly. Treatment of retinal ischemic manifestations. Adjuvant treatment in intermittent claudication due to peripheral occlusive arterial disease of the lower limbs. Contraindication Cardiogenic shock. Acute Phase mycordial infraction. Side Effects Rare side effects: minor gastrointestinal disorders in predisposed individuals or under taken between meals Generic Trivastal (Piribedil) Trivistal 50mg 120 pills 50mg 240 pills 50mg 60 pills 50mg 30 pills 50mg 90 pills Piribedil Trivastal
View more Anti Depressants No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
